Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 6
1991 20
1992 24
1993 27
1994 29
1995 31
1996 25
1997 33
1998 25
1999 31
2000 34
2001 52
2002 76
2003 108
2004 93
2005 90
2006 95
2007 116
2008 94
2009 91
2010 110
2011 125
2012 144
2013 121
2014 139
2015 174
2016 243
2017 296
2018 336
2019 122
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

2,677 results
Results by year
Filters applied: . Clear all
Page 1
Adoptive cell transfer as personalized immunotherapy for human cancer.
Rosenberg SA and Restifo NP. Science 2015 - Review. PMID 25838374 Free PMC article.
Adoptive cell therapy (ACT) is a highly personalized cancer therapy that involves administration to the cancer-bearing host of immune cells with direct anticancer activity. ...
Adoptive cell therapy (ACT) is a highly personalized cancer therapy that involves administration to the cancer-bearing host of immune
T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.
Houot R, et al. Cancer Immunol Res 2015 - Review. PMID 26438444 Free article.
Tumor immunotherapy has had demonstrable efficacy in patients with cancer. The most promising results have been with T-cell-based therapies. These include adoptive cell transfer of tumor-infiltrating lymphocytes, genetically engineered T cells, and immune checkpoint inhibitor antibodies. ...
Tumor immunotherapy has had demonstrable efficacy in patients with cancer. The most promising results have been with T-cell-based the …
Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer.
Singh N, et al. Curr Hematol Malig Rep 2017 - Review. PMID 29039115 Free PMC article.
PURPOSE OF REVIEW: In this review, we discuss the most recent developments in gene-editing technology and discuss their application to adoptive T cell immunotherapy. ...CTL019, or KYMRIAH™ (tisagenlecleucel), a CD19 CAR T cell product developed by Novartis and the University of Pennsylvania, was recently approved for clinical use by the Food and Drug Administration, representing a landmark in the application of adoptive T cell therapies. ...
PURPOSE OF REVIEW: In this review, we discuss the most recent developments in gene-editing technology and discuss their application to ad
New development in CAR-T cell therapy
Wang Z, et al. J Hematol Oncol 2017 - Review. PMID 28222796 Free PMC article.
However, tumor antigen escape has emerged as a main challenge for the long-term disease control of this promising immunotherapy in B cell malignancies. ...
However, tumor antigen escape has emerged as a main challenge for the long-term disease control of this promising immunotherapy in B …
Adoptive immunotherapy against sarcomas.
Mesiano G, et al. Expert Opin Biol Ther 2015 - Review. PMID 25516119
Several evidences support the concept that adoptive immunotherapy may effectively integrate within the complex and multidisciplinary treatment of sarcomas. ...EXPERT OPINION: Preclinical findings and initial clinical reports showed the potentialities and drawbacks of different adoptive immunotherapy strategies. ...
Several evidences support the concept that adoptive immunotherapy may effectively integrate within the complex and multidiscip …
Review of Immune Therapies Targeting Ovarian Cancer
Fan CA, et al. Curr Treat Options Oncol 2018 - Review. PMID 30430276
The rise of immunotherapy is the greatest advance in oncology to occur over the last several years, but applications in gynecologic malignancies lag behind other tumors. The term "immunotherapy" envelops monoclonal antibodies as receptor mediators, including immune checkpoint inhibitors (ICPI), cancer vaccines, and adoptive immunotherapies alone or in combination with other therapeutic approaches. ...
The rise of immunotherapy is the greatest advance in oncology to occur over the last several years, but applications in gynecologic m …
Adoptive cellular therapies: the current landscape.
Rohaan MW, et al. Virchows Arch 2019 - Review. PMID 30470934 Free PMC article.
Based on these rather novel insights, immunotherapeutic strategies have been developed. In the past decade, immune checkpoint blockade has demonstrated a major breakthrough in cancer treatment and has currently been approved for the treatment of multiple tumor types. Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) or gene-modified T cells expressing novel T cell receptors (TCR) or chimeric antigen receptors (CAR) is another strategy to modify the immune system to recognize tumor cells and thus carry out an anti-tumor effector function. ...
Based on these rather novel insights, immunotherapeutic strategies have been developed. In the past decade, immune checkpoint blockad …
2,677 results
Jump to page
Feedback